These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19905038)

  • 21. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
    Gordon J; McEwan P; Sabale U; Kartman B; Wolffenbuttel BH
    J Med Econ; 2016 Dec; 19(12):1167-1174. PubMed ID: 27356188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
    Goodall G; Costi M; Timlin L; Reviriego J; Sacristán JA; Smith-Palmer J; Dilla T
    Endocrinol Nutr; 2011; 58(7):331-40. PubMed ID: 21719364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
    Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
    J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
    Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
    Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.
    Best JH; Romley JA; Goldman DP; Conrad RM; Peters AL
    Am J Manag Care; 2012 Sep; 18(8 Suppl):s191-202. PubMed ID: 23039898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes.
    Kleinman NL; Schaneman JL; Lynch WD
    J Occup Environ Med; 2008 Dec; 50(12):1386-93. PubMed ID: 19092494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
    Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
    Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus.
    Lechleitner M; Roden M; Haehling E; Mueller M
    Wien Klin Wochenschr; 2005 Sep; 117(17):593-8. PubMed ID: 16395988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.
    Anderten H; Dippel FW; Kostev K
    J Diabetes Sci Technol; 2015 May; 9(3):644-50. PubMed ID: 25573957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.
    Rhoads GG; Dain MP; Zhang Q; Kennedy L
    Diabetes Obes Metab; 2011 Aug; 13(8):711-7. PubMed ID: 21410859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of exenatide in Asian Indians in a clinical care setting.
    Sudhakaran C; Fathima M; Anjana RM; Unnikrishnan RI; Mohan V
    Diabetes Technol Ther; 2010 Aug; 12(8):613-8. PubMed ID: 20615102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.